查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
胰腺癌诊断市场 - 2018-2028 年全球行业规模、份额、趋势、机会和预测，按测试类型、癌症类型、最终用户、地区和竞争细分
市场调查报告书
商品编码
1331403

胰腺癌诊断市场 - 2018-2028 年全球行业规模、份额、趋势、机会和预测，按测试类型、癌症类型、最终用户、地区和竞争细分

Pancreatic Cancer Diagnostics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Test Type, By Cancer Type, By End User, Region and Competition
出版日期: | 出版商: TechSci Research | 英文 113 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

由于胰腺癌发病率不断上升、对微创诊断程序的需求不断增加以及研发投资不断增加，全球胰腺癌诊断市场在预测期内将以令人印象深刻的速度增长。

与胰腺癌相关的研究和开发不断增加

胰腺癌是一种高度侵袭性的癌症，难以诊断和治疗。然而，最近的研究表明胰腺癌诊断领域取得了有希望的发展。液体活检、人工智能、生物标誌物、成像技术和个性化医疗都是积极研究的领域，可能最终改善胰腺癌患者的预后。

液体活检是一种非侵入性诊断工具，涉及对患者血液中的循环肿瘤细胞 (CTC) 和游离 DNA (cfDNA) 进行分析。最近的研究表明，液体活检可以比传统成像方法更早期地检测胰腺癌。

人工智能（AI）正在应用于胰腺癌诊断领域，以提高现有诊断方法的准确性和效率。最近的研究表明，人工智能算法可以根据医学影像数据准确预测胰腺癌的可能性。 2020 年发表在《临床肿瘤学杂誌》上的一项研究发现，人工智能算法能够根据 CT 扫描预测胰腺癌的可能性，准确率达 90%。

生物标誌物是可用于指示疾病存在的生物分子。最近的研究已经确定了几种可能有助于胰腺癌诊断的生物标誌物。 2021 年发表在《胃肠病学杂誌》上的一项研究发现，三种生物标誌物（CA19-9、CEA 和 FGF21）的组合可以准确预测胰腺囊肿患者患胰腺癌的可能性。 2020 年发表在《蛋白质组研究杂誌》上的另一项研究发现了几种可能有助于早期检测胰腺癌的生物标誌物。

医学成像技术的进步也正在改善胰腺癌的诊断。最近的研究表明，超声内镜（EUS）是一种用于检测胰腺癌的高精度成像技术。 2020 年发表在《胃肠病学杂誌》上的一项研究发现，EUS 在可疑胰腺肿块患者中能够以 94% 的准确率检测出胰腺癌。

个性化医疗涉及根据个人独特的基因构成定制医疗治疗。最近的研究表明，个性化医疗可能有助于胰腺癌的诊断。 2021年发表在《国家癌症研究所杂誌》上的一项研究发现，个性化疫苗可以刺激免疫系统攻击胰腺癌细胞。

胰腺癌的患病率不断上升

胰腺癌患病率的不断上升可能会对胰腺癌诊断市场产生重大影响。随着胰腺癌发病率持续上升，越来越需要更好、更有效的诊断工具，以便在治疗最有效的早期阶段检测到这种疾病。

有多种因素导致胰腺癌患病率不断上升，包括人口老龄化、2 型糖尿病患病率不断上升、肥胖以及吸烟和饮酒等不健康的生活方式。预计这些发展将持续下去，从而推动胰腺癌诊断需求的增加。

为了满足这一需求，胰腺癌诊断市场在未来几年可能会增长。目前已有多种可用于胰腺癌的诊断工具，包括 CT 扫描、MRI 和 PET 扫描等影像学检查，以及测量某些生物标誌物水平的血液检查。然而，仍然需要更准确和可靠的诊断工具，特别是对于早期胰腺癌。

目前正在进行研究和开发工作，开发新的胰腺癌诊断工具，例如检测血液中循环肿瘤 DNA 的液体活检，以及可以提供更详细和准确的胰腺图像的新成像技术。

随着研究人员和公司致力于开发更好的工具来检测和治疗这种致命疾病，胰腺癌的日益流行可能会推动胰腺癌诊断市场的创新和投资，这将支持全球胰腺癌诊断市场的增长未来几年。

可用的定制：

根据给定的市场数据，TechSci Research 可根据公司的具体需求提供定制服务。该报告可以使用以下自定义选项：

公司信息

  • 其他市场参与者（最多五个）的详细分析和概况分析。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场细分

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要行业合作伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量和验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球胰腺癌诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按测试类型（诊断影像测试、活检、血液测试、肝功能测试等）
    • 按癌症类型（外分泌癌、腺癌、鳞状细胞癌、胶体癌、其他）
    • 按最终用户（医院和诊所、诊断中心、其他）
    • 按地区
    • 按公司划分 (2022)
  • 产品图
    • 按测试类型
    • 按癌症类型
    • 按最终用户
    • 按地区

第 6 章：北美胰腺癌诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按测试类型
    • 按癌症类型
    • 按最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲胰腺癌诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按测试类型
    • 按癌症类型
    • 按最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙

第 8 章：亚太地区胰腺癌诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按测试类型
    • 按癌症类型
    • 按最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳大利亚

第 9 章：南美胰腺癌诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按测试类型
    • 按癌症类型
    • 按最终用户
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲胰腺癌诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按测试类型
    • 按癌症类型
    • 按最终用户
    • 按国家/地区
  • MEA：国家分析
    • 南非胰腺癌诊断
    • 沙特阿拉伯胰腺癌诊断
    • 阿联酋胰腺癌诊断

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 近期发展
  • 併购
  • 产品发布

第 13 章：全球胰腺癌诊断市场：SWOT 分析

第 14 章：波特的五力分析

  • 行业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第15章：竞争格局

  • 商业概览
  • 产品供应
  • 最近的发展
  • 主要人员
  • SWOT分析
    • Siemens Healthcare GmbH
    • FUJIFILM Corporation
    • Laboratory Corporation of America Holdings
    • Abbott Laboratories, Inc.
    • Agilent Technologies, Inc.
    • Thermo Fisher Scientific Inc.
    • Immunovia, Inc.

第 16 章：战略建议

简介目录
Product Code: 15209

Global Pancreatic Cancer Diagnostics Market is poised to grow at an impressive rate during the forecast period on account of the increasing incidence of pancreatic cancer, rising demand for minimally invasive diagnostic procedures, and growing investment in research and development.

Pancreatic cancer is a deadly disease that affects the pancreas, a vital organ located in the abdomen that plays a critical role in digestion and metabolism. Unfortunately, pancreatic cancer is notoriously difficult to detect in its early stages, and by the time it is diagnosed, it has often spread to other parts of the body. This is why early detection is critical to improving survival rates, and the demand for pancreatic cancer diagnostics has increased significantly in recent years.

One of the main factors that has increased the demand for pancreatic cancer diagnostics is the rising incidence of the disease. The increasing incidence of pancreatic cancer has led to a growing demand for diagnostic tests that can detect the disease in its early stages.

Another factor that has contributed to the demand for pancreatic cancer diagnostics is the aging population. The majority of instances of pancreatic cancer occur in those over 60, making it more common among older adults. The need for early-pancreatic cancer detection diagnostic tools is projected to grow as the world's population ages.

Advances in diagnostic technologies have also played a significant role in the increased demand for pancreatic cancer diagnostics. In recent years, new imaging techniques such as magnetic resonance imaging (MRI), endoscopic ultrasound (EUS), and Ultrasound have been developed that allow for earlier and more accurate detection of pancreatic cancer. These advances have led to an increased demand for these tests and have made it easier for doctors to diagnose pancreatic cancer in its early stages.

The increased need for diagnostic tests is also a result of rising awareness of pancreatic cancer and its symptoms. People requesting diagnostic tests for pancreatic cancer have increased as a result of organizations like the Pancreatic Cancer Action Network and the Lustgarten Foundation raising awareness of the condition and the value of early identification.

Investment in research and development has also played a key role in the increased demand for pancreatic cancer diagnostics. Biotechnology and pharmaceutical companies are investing heavily in the development of new diagnostic tests and treatments for pancreatic cancer, which has led to a growing number of diagnostic options for patients.

In the last three years, there have been several product launches related to pancreatic cancer diagnostics. These products range from new imaging techniques to blood tests that can detect the disease in its early stages.

In 2021, researchers from the University of Michigan developed a new blood test called the Pancreas-Specific Lipase Test (PSLT) that can detect early-stage pancreatic cancer with high accuracy. The test measures the levels of a protein called pancreatic lipase in the blood, which is often elevated in patients with pancreatic cancer. The PSLT has the potential to improve early detection of pancreatic cancer, which is critical in improving patient outcomes.

In 2020, researchers from the University of Virginia School of Medicine developed a new imaging technique called MR-guided Focused Ultrasound (MRgFUS), which uses focused ultrasound waves to destroy cancer cells in the pancreas. The technique is non-invasive and can be performed without the need for surgery or radiation therapy. MRgFUS has the potential to improve the treatment of pancreatic cancer and may offer a less invasive alternative to traditional treatment methods.

Pancreatic cancer diagnostics faces a number of challenges, including the lack of early symptoms, limited diagnostic tools, lack of reliable biomarkers, difficulty in distinguishing between pancreatic cancer and other pancreatic conditions, and the limited effectiveness of current treatment options.

Rising Research and Development related to Pancreatic Cancer

Pancreatic cancer is a highly aggressive cancer that is difficult to diagnose and treat. However, recent research has shown promising developments in the field of pancreatic cancer diagnostics. Liquid biopsy, artificial intelligence, biomarkers, imaging techniques, and personalized medicine are all areas of active research that may ultimately improve patient outcomes in pancreatic cancer.

Liquid biopsy is a non-invasive diagnostic tool that involves the analysis of circulating tumor cells (CTCs) and cell-free DNA (cfDNA) in a patient's blood. Recent research has shown that liquid biopsy can be used to detect pancreatic cancer at an earlier stage than traditional imaging methods.

Artificial intelligence (AI) is being used in the field of pancreatic cancer diagnostics to improve the accuracy and efficiency of existing diagnostic methods. Recent research has shown that AI algorithms can accurately predict the likelihood of pancreatic cancer based on medical imaging data. A study published in the Journal of Clinical Oncology in 2020 found that an AI algorithm was able to predict the likelihood of pancreatic cancer with 90% accuracy based on CT scans.

Biomarkers are biological molecules that can be used to indicate the presence of a disease. Recent research has identified several biomarkers that may be useful in pancreatic cancer diagnostics. A study published in the Journal of Gastroenterology in 2021 found that a combination of three biomarkers (CA19-9, CEA, and FGF21) can accurately predict the likelihood of pancreatic cancer in patients with pancreatic cysts. Another study published in the Journal of Proteome Research in 2020 identified several biomarkers that may be useful in the early detection of pancreatic cancer.

Advances in medical imaging techniques are also improving pancreatic cancer diagnostics. Recent research has shown that endoscopic ultrasound (EUS) is a highly accurate imaging technique for the detection of pancreatic cancer. A study published in the Journal of Gastroenterology in 2020 found that EUS was able to detect pancreatic cancer with 94% accuracy in patients with suspicious pancreatic masses.

Personalized medicine involves tailoring medical treatment to an individual's unique genetic makeup. Recent research has shown that personalized medicine may be useful in pancreatic cancer diagnostics. A study published in the Journal of the National Cancer Institute in 2021 found that a personalized vaccine can stimulate the immune system to attack pancreatic cancer cells.

Growing Prevalence of Pancreatic Cancer

The growing prevalence of pancreatic cancer is likely to have a significant impact on the market for pancreatic cancer diagnostics. As the incidence of pancreatic cancer continues to rise, there is a growing need for better and more efficient diagnostic tools to detect this disease at an early stage when treatment is most effective.

There are several factors driving the increasing prevalence of pancreatic cancer, including an aging population, a growing prevalence of type 2 diabetes, obesity, and unhealthy lifestyle choices like smoking and alcohol use. These developments are anticipated to persist, fueling an increase in demand for pancreatic cancer diagnostics.

In response to this demand, the market for pancreatic cancer diagnostics is likely to grow in the coming years. There are already several diagnostic tools available for pancreatic cancer, including imaging tests like CT scans, MRIs, and PET scans, as well as blood tests that measure levels of certain biomarkers. However, there is still a need for more accurate and reliable diagnostic tools, particularly for early-stage pancreatic cancer.

Research and development efforts are underway to develop new diagnostic tools for pancreatic cancer, such as liquid biopsies that detect circulating tumor DNA in the blood and new imaging technologies that can provide more detailed and accurate images of the pancreas.

The growing prevalence of pancreatic cancer is likely to drive innovation and investment in the market for pancreatic cancer diagnostics as researchers and companies work to develop better tools for detecting and treating this deadly disease, and this will support the growth of global pancreatic cancer diagnostics market in the coming years.

Market Segmentation

Global Pancreatic Cancer Diagnostics Market can be segmented by test type, cancer type, end user, region, and competitive landscape. Based on test type, the market can be divided into Diagnostic Imaging Tests, Biopsy, Blood Tests, Liver Function Tests, and Others. Based on cancer type the market is divided into Exocrine, Adenocarcinoma, Squamous Cell Carcinoma, Colloid Carcinoma, and Others. Based on end-user, the market is divided into Hospitals & Clinics, Diagnostic Centers, and Others.

Market Players

Siemens Healthcare GmbH, FUJIFILM Corporation, Laboratory Corporation of America Holdings, Abbott Laboratories, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Immunovia, Inc., are some of the leading players operating in the Global Pancreatic Cancer Diagnostics Market.

Report Scope:

In this report, Global Pancreatic Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Pancreatic Cancer Diagnostics Market, By Test Type:

  • Diagnostic Imaging Tests
  • CT scan
  • MRI
  • Ultrasound
  • Others
  • Biopsy
  • Blood Tests
  • Liver Function Tests
  • Others

Pancreatic Cancer Diagnostics Market, By Cancer Type:

  • Exocrine
  • Adenocarcinoma
  • Squamous Cell Carcinoma
  • Colloid Carcinoma
  • Others

Pancreatic Cancer Diagnostics Market, By End User:

  • Hospitals & Clinics
  • Diagnostic Centers
  • Others

Pancreatic Cancer Diagnostics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Pancreatic Cancer Diagnostics Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pancreatic Cancer Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (Diagnostic Imaging Tests, Biopsy, Blood Tests, Liver Function Tests, Others)
      • 5.2.1.1. By Diagnostic Imaging Tests (CT scan, MRI, Ultrasound, Others)
    • 5.2.2. By Cancer Type (Exocrine, Adenocarcinoma, Squamous Cell Carcinoma, Colloid Carcinoma, Others)
    • 5.2.3. By End User (Hospitals & Clinics, Diagnostic Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Product Map
    • 5.3.1. By Test Type
    • 5.3.2. By Cancer Type
    • 5.3.3. By End User
    • 5.3.4. By Region

6. North America Pancreatic Cancer Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By Cancer Type
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pancreatic Cancer Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
        • 6.3.1.2.2. By Cancer Type
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Pancreatic Cancer Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
        • 6.3.2.2.2. By Cancer Type
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Pancreatic Cancer Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type
        • 6.3.3.2.2. By Cancer Type
        • 6.3.3.2.3. By End User

7. Europe Pancreatic Cancer Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By Cancer Type
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Pancreatic Cancer Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
        • 7.3.1.2.2. By Cancer Type
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Pancreatic Cancer Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
        • 7.3.2.2.2. By Cancer Type
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Pancreatic Cancer Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Test Type
        • 7.3.3.2.2. By Cancer Type
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Pancreatic Cancer Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
        • 7.3.4.2.2. By Cancer Type
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Pancreatic Cancer Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type
        • 7.3.5.2.2. By Cancer Type
        • 7.3.5.2.3. By End User

8. Asia-Pacific Pancreatic Cancer Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By Cancer Type
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Pancreatic Cancer Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
        • 8.3.1.2.2. By Cancer Type
        • 8.3.1.2.3. By End User
    • 8.3.2. India Pancreatic Cancer Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
        • 8.3.2.2.2. By Cancer Type
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Pancreatic Cancer Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
        • 8.3.3.2.2. By Cancer Type
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Pancreatic Cancer Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
        • 8.3.4.2.2. By Cancer Type
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Pancreatic Cancer Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type
        • 8.3.5.2.2. By Cancer Type
        • 8.3.5.2.3. By End User

9. South America Pancreatic Cancer Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By Cancer Type
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Pancreatic Cancer Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
        • 9.3.1.2.2. By Cancer Type
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Pancreatic Cancer Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
        • 9.3.2.2.2. By Cancer Type
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Pancreatic Cancer Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type
        • 9.3.3.2.2. By Cancer Type
        • 9.3.3.2.3. By End User

10. Middle East and Africa Pancreatic Cancer Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type
    • 10.2.2. By Cancer Type
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Pancreatic Cancer Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
        • 10.3.1.2.2. By Cancer Type
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Pancreatic Cancer Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
        • 10.3.2.2.2. By Cancer Type
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Pancreatic Cancer Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type
        • 10.3.3.2.2. By Cancer Type
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Pancreatic Cancer Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Product Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. Siemens Healthcare GmbH
    • 15.5.2. FUJIFILM Corporation
    • 15.5.3. Laboratory Corporation of America Holdings
    • 15.5.4. Abbott Laboratories, Inc.
    • 15.5.5. Agilent Technologies, Inc.
    • 15.5.6. Thermo Fisher Scientific Inc.
    • 15.5.7. Immunovia, Inc.

16. Strategic Recommendations